Abstract

Simple SummaryVarious immune cells are involved in host immune responses to cancer. T-helper (Th) 1 cells, cytotoxic CD8+ T cells, and natural killer cells are the major effector cells in anti-tumor immunity, whereas cells such as regulatory T cells and myeloid-derived suppressor cells are negatively involved in anti-tumor immunity. Th2 cells and Th17 cells have been shown to have both pro-tumor and anti-tumor activities. The migratory properties of various immune cells are essential for their function and critically regulated by the chemokine superfamily. In this review, we summarize the roles of various immune cells in tumor immunity and their migratory regulation by the chemokine superfamily. We also assess the therapeutic possibilities of targeting chemokines and chemokine receptors in cancer immunotherapy.Various immune cells are involved in host tumor immune responses. In particular, there are many T cell subsets with different roles in tumor immunity. T-helper (Th) 1 cells are involved in cellular immunity and thus play the major role in host anti-tumor immunity by inducing and activating cytotoxic T lymphocytes (CTLs). On the other hand, Th2 cells are involved in humoral immunity and suppressive to Th1 responses. Regulatory T (Treg) cells negatively regulate immune responses and contribute to immune evasion of tumor cells. Th17 cells are involved in inflammatory responses and may play a role in tumor progression. However, recent studies have also shown that Th17 cells are capable of directly inducting CTLs and thus may promote anti-tumor immunity. Besides these T cell subsets, there are many other innate immune cells such as dendritic cells (DCs), natural killer (NK) cells, and myeloid-derived suppressor cells (MDSCs) that are involved in host immune responses to cancer. The migratory properties of various immune cells are critical for their functions and largely regulated by the chemokine superfamily. Thus, chemokines and chemokine receptors play vital roles in the orchestration of host immune responses to cancer. In this review, we overview the various immune cells involved in host responses to cancer and their migratory properties regulated by the chemokine superfamily. Understanding the roles of chemokines and chemokine receptors in host immune responses to cancer may provide new therapeutic opportunities for cancer immunotherapy.

Highlights

  • Tumor immunity is initiated by the recognition of tumor antigens by the immune system [1]

  • As described in this article, a diverse array of immune cells is known to be involved in host tumor immunity and infiltrates into tumor tissues, generating a highly complex cell population in the tumor microenvironment [198]

  • These cells express selective but often overlapping chemokine receptors and infiltrate into tumor tissues via chemokines produced by cells including tumor cells, infiltrating immune cells, and stromal cells [198]

Read more

Summary

Introduction

Tumor immunity is initiated by the recognition of tumor antigens by the immune system [1]. Composed of various functional subsets including T-helper (Th) 1 cells, Th2 cells, Th17 cells, and regulatory T (Treg) cells [4,5] These T cell subsets are characterized by the secretion of signature cytokines and differentially involved in tumor immunity [4,5]. Tumor tissues are highly enriched with innate immune cells such as myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and tumor-associated neutrophils (TANs) [6,7] These various immune cells are known to express characteristic chemokine receptors and are elaborately regulated in their migration and tissue localization by respective chemokine ligands [8,9,10]. We overview the roles of various immune cells and the chemokine superfamily in host immune responses to tumor cells in order to assess the possibility of targeting chemokines and chemokine receptors for cancer immunotherapy

Induction of Tumor-Specific T Cell Responses
Chemokine-mediated
Th2 Cell
Th17 Cell
Pro-Tumor Activity
Anti-Tumor Activity
Treg Cell
The Chemokine Superfamily as Therapeutic Targets in Cancer Immunotherapy
CCR4 and CCR8
CXCR2 and CXCR4
CCR2 and CCR5
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call